The purpose of this study is to compare the safety and efficacy of CombiflexOmega in comparison to SmofKabiven in postoperative patients requiring parenteral nutrition.

Inclusion Criteria:

• Patients aged 20 and older
• Patients are expected to require PN for more than 5 days
• Patients who voluntarily signed the consent form

Exclusion Criteria:

• Patients are expected difficult to survive more than 5 days

• Pregnant or breast-feeding women

• BMI > 30 kg/m2

• Patients with severe blood coagulation disorders

• Patients with congenital amino acid metabolism disorders

• Patients with acute shock

• Patients with uncontrollable diabetes mellitus

• Patients with hemophage syndrome

• Patients with hypopotassemia (K < 3.0mEq/L)

• Patients having the history of myocardial infarction

• Patients reported the following laboratory value

  • fasting TG > 250mg/dl, TC > 300mg/dl
  • ALT/AST ≥ 2×ULN, Bilirubin ≥ 3mg/dl (Exception : patients with periampullary carcinoma including biliary tract or pancreas)
  • Creatinine ≥ 1.5mg/dl
  • Ca > 11.2mg/dl, Na ≥ 145mEq/L, Mg ≥ 2.1mEq/L, K ≥ 5.5mEq/L

• Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug

• Patients having the history of drug or alcohol abuse

• General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, cardiac decompensation

• Patients are in unstable conditions

• Patients with difficult peripheral intravenous

• Patients with parenteral nutrition within 7 days prior to start of the trial

• Participation in another clinical study with an investigational drug or an investigational medical device within 28 days prior to start of study

• Patients judged to be unsuitable for this trial by investigators